Conditions: Rheumatoid Arthritis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 219
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether the Spleen Tyrosine Kinase (Syk) Inhibitor, R935788 (R788) at a dose of 100 mg, tablet, orally, twice-a-day is effective in the treatment of Rheumatoid Arthritis in patients who have 'failed' a biologic therapy.

Detailed description:

Arms:
arm 1: Fostamatinib disodium (R935788) 100 mg tablet, orally, twice-a-day arm 2: Placebo, orally, twice-a-day

Interventions: intervention 1: Fostamatinib disodium (R935788) intervention 2: Placebo
Intervention descriptions: intervention 1: R935788 100 mg tablet, orally, twice-a-day intervention 2: Placebo, orally, twice-a-day

Protocol document: